Non small cell lung cancer is a type of cancer that commonly affects the lungs and spreads more slowly than its counterpart, small cell lung cancer. This particular form accounts for about 85% of all lung cancers, making it the most prevalent subtype. Non small cell lung cancer can be further categorized into three main types: adenocarcinoma, squamous cell carcinoma, and large cell carcinoma. Adenocarcinoma often starts in cells that produce mucus and is typically found on the outer parts of the lungs. Squamous cell carcinoma usually arises in the lining of bronchial tubes and tends to cause symptoms like coughing or shortness of breath earlier on. Large cell carcinoma refers to tumors that are difficult to classify as either adenocarcinoma or squamous cell carcinoma due to their unique characteristics. Although non small cell lung cancer progresses at a slower pace, proper diagnosis at an early stage remains vital for effective treatment options such as surgery, radiation therapy, chemotherapy, targeted therapies or immunotherapy tailored according to individual cases and preferences.
1.
Video: Liver transplant for patients with advanced colorectal cancer
2.
La interacción GBP3-STING en el glioblastoma coordina la respuesta deficiente al temozolomide.
3.
Blood tests can predict the risk of relapse after a bone marrow transplant in patients with acute myeloid leukemia.
4.
AI is useful in low-resource areas for triaging breast masses.
5.
Does pollution cause cancer?
1.
Methemoglobinemia in OR & ICU: Pathophysiology, Detection, and Management Review
2.
Bridging the Gap Between Cancer Treatment-Induced Cardiotoxicity and Regenerative Medicine
3.
Unlocking the Secrets of Neutrophils: Exploring Their Role in Immune Defense
4.
Unlocking the Potential of Onivyde: A New Hope for Cancer Treatment
5.
Beyond the Cure: The Emerging Role of Tissue-Agnostic Therapies in Palliative Oncology
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part IV
2.
CDK4/6 Inhibitors in Extending Overall Survival in HR+/HER2- aBC Patients in Clinical Trial and Real World
3.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part I
4.
Navigating the Complexities of Ph Negative ALL - Part VII
5.
An In-Depth Look At The Signs And Symptoms Of Lymphoma- The Q & A Session
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation